Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Diltiazem on BMS-986141 PK in Healthy Subjects
NCT02922452Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bms-986141 in ischemic stroke, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration, Area under the concentration-time curve from time zero extrapolated to infinite time and 1 more. Started Sep 2016; status: completed.
02
Drugs
bms-986141
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02922452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02922452.